ResApp announces FDA 510(k) submission for SleepCheckRx

View printer-friendly version ResApp has submitted a 510(k) premarket notification to the US FDA for SleepCheckRx SleepCheckRx is a smartphone-only solution that uses clinically accurate algorithms to assess a patient’s risk of obstructive sleep apnoea by analysing...

First patients recruited in COVID-19 clinical study in India

View printer-friendly version First patients recruited in Indian study to collect cough sounds from patients with suspected COVID-19 Study aims to recruit 220 participants, with recruitment expected to be complete by the end of October ResApp aims to use the data to...

ResApp receives Advanced and Overseas R&D finding

View printer-friendly version Brisbane, Australia, 14 September 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease is pleased to announce that it has...

ResAppDx receives regulatory approval in Indonesia

View printer-friendly version Brisbane, Australia, 1 September 2021 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce receipt of...

Alodokter to launch ResAppDx in Indonesia

View printer-friendly version Alodokter is the largest provider of telehealth services in Indonesia Launched in 2014, Alodokter brings high-quality medical services to more than 30 million monthly active users by providing an integrated mobile solution for patients...